Targets for endothelin in the diseased kidney: Clues for therapeutic intervention

Experimental Nephrology

Volumn 7, Issue 1, 1999, Pages 1-10

  Rohmeiss, P ^b   Birck, R ^c   Braun, C ^c   Kirchengast, M ^a   Van Der Woude, F J ^c  

^a Knoll AG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NONE

Author keywords

Endothelin receptor antagonists; Endothelin 1; Renal insufficiency

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST;

CHRONIC KIDNEY FAILURE; DRUG EFFECT; ENDOTHELIUM CELL; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SODIUM TRANSPORT; TARGET CELL; VASOCONSTRICTION;

EID: 0032899418     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020577     Document Type: Review

References (130)

1. Vane JR, Anggard EA, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
2. Moncada S, Gryglewski R, Bunting S, Vane J: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-665.
3. Palmer R, Ferrige A, Moncada S: Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327: 524-526.
4. Gillespie M, Owasoyo J, McMurty I, O'Brian R: Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther 1986;236:339-343.
5. Rubanyi G, Vanhoutte PM: Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol Lond 1985;364: 45-56.
6. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
7. Kohan DE: Endothelins in the kidney: Physiology and pathophysiology. Am J Kidney Dis 1993;4:493-510.
8. Kurihara H, Yamaoiki K, Nagai R, Yoshizmi M. Takaku F, Satoh H, Inui J, Yazaki Y: Endothelin: A potent vasoconstrictor associated with coronary vasospasm. Life Sci 1989;44: 1937-1944.
9. Krämer BK, Ackermann M, Kohler SM, Riegger GAJ: Role of endothelin in hypertension. Clin Invest 1994;72:88-93.
10. Hocher B, Rohmeiss P, Zart R, Diekmann F, Vogt V, Metz D, Fakhury M, Gretz N, Bauer C, Koppenhagen K, Neumayer HH, Distler A: Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 1996;31:499-510.
11. Hocher B, Thöne-Reineke C, Bauer C, Raschack M, Neumayer HH: The paracrine endothelin system: Pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem 1997;35:175-189.
12. Stewart DJ: Endothelin in cardiopulmonary disease: Factor paracrine vs. neurohormonal. Eur Heart J 1993;14:48-54.
13. Asano T, Ikegaki I, Satoh S, Suzuku Y, Shibuya M, Sugita K, Hidaka H: Endothelin: A potential modulator of cerebral spasm. Eur J Pharmacol 1990;190:365-372.
14. Kitamura K, Tanaka K, Kato J, Eto T, Tanaka K: Regional distribution of immunoreactive endothelin in porcine tissue: Abundance in inner medulla of the kidney. Biochem Biophys Res Commun 1989;161:348-352.
15. Yoshimi H, Hirata Y, Fukuda Y: Regional distribution of immunoreactive endothelin in rats. Peptides 1989;10:805-808.
16. Marsden PA, Dorfman DM, Collins T, Brenner BM, Orkin SH, Ballermann BJ: Regulated expression of endothelin-1 in glomerular capillary endothelial cells. Am J Physiol 1991;261: F117-F125.
17. Kohan DE, Fiedorek FTJ: Endothelin synthesis by rat inner medullary collecting duct cells. J Am Soc Nephrol 1991;2:150-155.
18. Kasinath BS, Fried TA, Davalath S, Marsden PA: Glomerular epithelial cells synthesize endothelin peptides. Am J Pathol 1992;141:279-283.
19. Kohan DE: Production of endothelin-1 by rat mesangial cells: Regulation by tumor necrosis factor. J Lab Clin Med 1992;119:477-484.
20. Sugiura M, Snadjar RM, Schwartzberg M, Badr KF, Inagami T: Identification of two types of specific endothelin receptors in rat mesangial cells. Biochem Biophys Res Commun 1989;162:1396-1401.
21. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD: Functional endothelin-1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992;7:288-292.
22. Summer MJ, Cannon TR, Mundin JW, White DG, Watts IA: Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107:858-860.
23. Terada Y, Tomita K, Nonoguchi H, Marumo F: Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest 1992;90:107-112.
24. Pernow J, Franco-Cerceda A, Matran R, Lundberg JM: Effect of endothelin-1 on regional vascular resistances in the pig. J Cardiovasc Pharmacol 1989;13:S205-S206.
25. Madeddu P, Troffa C, Glorioso N, Pazzola A, Soro A, Manunta P, Tonolo G, Demontis MP, Varoni MV, Anania V: Effect of endothelin on regional hemodynamics and renal function in awake normotensive rats. J Cardiovasc Pharmacol 1989;14:818-825.
26. Rohmeiss P, Photiadis J, Rohmeiss S, Unger T: Hemodynamic actions of intravenous endothelin in rats: Comparison with sodium nitroprusside and methoxamine. Am J Physiol 1990; 258:H337-H346.
27. Braun C, Lang C, Hocher B, Gretz N, van der Woude FJ, Rohmeiss P: Influence of the renal endothelin system on the autoregulation of renal blood flow in spontaneously hypertensive rats. Kidney Blood Press Res 1997;20:6-10.
28. Kohan DE: Endothelins in the normal and diseased kidney. Am J Kidney Dis 1996;1:2-26.
29. Gray GA, Webb DJ: The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996;2: 109-148.
30. Masaki T, Yanagisawa M: Physiology and pharmacology of endothelins. Med Res Rev 1992;4:391-421.
31. Simonson MS: Endothelins: Multifunctional renal peptides. Physiol Rev 1993;2:375-411.
32. Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
33. Inoue A, Yanagisawa M, Kimura S, Kasuya J, Miyancki T, Goto K, Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867.
34. Block KD, Freidrich SP, Lee ME, Eddy RL, Shows TB, Quertermous T: Structural organisation and chromosomal assignment of the gene encoding endothelin. J Biol Chem 1989; 264:10851-10857.
35. Block KD, Hong CC, Eddy RL, Shows TB, Quertermous T: cDNA cloning and chromosomal assignment of the endothelin-2 gene: Vasoactive intestinal contractor peptide is rat endothelin 2. Genomics 1991;10:236-242.
36. Block KD, Eddy RL, Shows TB, Quertermous T: cDNA cloning and chromosomal assignment of the gene encoding endothelin-3. J Biol Chem 1989;264:18156-18161.
37. Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A: Sarafotoxin, a novel vasoconstrictor peptide: Phosphoinositide hydrolysis in rat heart and brain. Science 1988; 242:268-270.
38. Lemonnier Degouville AC, Lippton HL, Cavero I, Summer WR, Hyman AL: Endothelin - A new family of endothelium-derived peptides with widespread biological properties. Life Sci 1989;45:1499-1513.
39. Opgenorth T, Wu Wong JR, Shiosaki K: Endothelin-converting enzymes. FASEB J 1992;6: 2653-2659.
40. Shimada K, Takahashi M, Tanzawa K: Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994;269:18275-18278.
41. Shimada K, Matsushita Y, Wakabayashi K, Takahashi ML. Matsubara A, Iijima Y, Tanzawa K: Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem Biophys Res Commun 1995;207: 807-812.
42. Emoto N, Yanagisawa M: Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995;270:15262-15268.
43. Weitzberg E, Ahlborg G, Lundberg JM: Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 1991;180:1298-1303.
44. Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhausl W: Regional hemodynamic effects and clearance of endothelin-1 in humans: Renal and peripheral tissue may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 1992;19:176-180.
45. Hirata Y, Yoshimi H, Takaichi S, Yanagisawa M, Masaki T: Binding and receptor down-regulation of the novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Lett 1988;239:13-17.
46. Ando K, Hirata Y, Takei Y, Kawakami M, Marumo F: Endothelin-1-like immunoreactivity in human urine. Nephron 1991;57:36-39.
47. Lam HC, Takahashi K, Ghatei MA, Warrens AN, Rees AJ, Bloom SR: Immunoreactive endothelin in human plasma urine, milk and saliva. J Cardiovasc Pharmacol 1991;17:S390-S393.
48. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732.
49. Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S, Imura H: Organization, structure, chromosomal assignment and expression of the gene encoding the human endothelin A receptor. J Biol Chem 1992;267: 18797-18804.
50. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990;348:732-735.
51. Bax WA, Saxena PR: The current endothelin receptor classification: Time for reconsideration? Trends Pharmacol Sci 1994;15:379-386.
52. Karne S, Jaywickreme CK, Lerner MR: Cloning and characterization of an endothelin-3 specific receptor (ETC-receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993;268:19126-19133.
53. Kumar C, Mwangi V, Nuthalaguni P, Wu HL, Pullen M, Brun K, Aiyar H, Morris RA, Naughton R, Nambi P: Cloning and characterization of a novel endothelin receptor from Xenopus heart. J Biol Chem 1994;269:13414-13420.
54. King AJ, Brenner BM, Anderson S: Endothelin: A potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989;256:F1051-F1058.
55. Simonson MS, Wann S. Mene P, Dubyak GR, Rester M, Nakazato Y, Sedor JR, Dunn MJ: Endothelin stimulates phospholipase C, Na/H exchange, c-fos expression and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708-712.
56. Ruiz-Ortega M, Gomez-Garre D, Alcazar R, Palacios I, Bustos C, Gonzalez S, Plaza JJ, Gonzalez E, Egido J: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens 1994;12: 551-558.
57. Warner A, de Nucci G, Vane JR: Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol 1989;159: 325-326.
58. De Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797-9800.
59. Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS: Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107:858-860.
60. Pollock DA, Opgenorth TJ: Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. J Physiol 1993;264:R222-R226.
61. Warner TD: Endothelin receptor antagonists. Cardiovasc Drug Rev 1994;2:105-122.
62. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagal R, Oda H, Kuwaki T, Cao W, Kamada N, Jishage K, Ouchi Y, Azumo S: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-710.
63. Puffenberger EG, Hosoda K, Washington SS, Nakao K, de Wit D, Yanagisawa M, Chakravart A: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 1994;7:1257-1266.
64. Hocher B, Thöne-Rheineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neuymayer HH, Schleuning WD, Theuring F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis and renal cysts but not hypertension. J Clin Invest 1997;6:1380-1389.
65. Wagner OF, Christ G, Wojta T: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-16068.
66. Lerman A, Hildebrand FLJ, Aarhus LL, Burnett JCJ: Endothelin has biological actions at pathophysiological concentrations. Circulation 1991;83:1808-1814.
67. Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F: Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989;1127:1989.
68. Margulies KB, Hildebrand FLJ, Heublein DM, Burnett JCJ: Radiocontrast increases plasma and urinary endothelin-1. J Am Soc Nephrol 1991;2:1041-1045.
69. Watschinger B, Vychytil A, Schuller M, Hartter E, Traindl O: The pathophysiological role of endothelin in acute vascular rejection after renal transplantation. Transplantation 1991;52: 743-746.
70. Takayama K, Nagai T, Kinugasa E, Akizawa T, Koshikawa S: Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. ASAIO Trans 1991;37:M187-M188.
71. Ohta K, Hirata Y, Schichiri M, Ichioka M, Kubota T, Marumo F: Cisplatin-induced urinary endothelin excretion. JAMA 1991;265: 1391-1392.
72. Siegler RL, Edwin SS, Christofferson RD, Mitchell MD: Endothelin in the urine of children with the hemolytic uremic syndrome. Pediatrics 1991;88:1063-1066.
73. Yokokawa K, Tahara H, Kohno M, Murakawa K, Yasunari K, Nakagawa K, Hamada T, Otani S, Yanagisawa M, Takeda T: Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 1991;114:213-215.
74. Kon V, Yoshioka T, Fogo A, Ichikawa I: Glomerular actions of endothelin in vivo. J Clin Invest 1989;83:1762-1767.
75. Shibouta Y, Suzuki N, Shino A, Matsumoto H, Terashita Z, Kondo K, Nishikawa K: Pathophysiological role of endothelin in acute renal failure. Life Sci 1990;46:1611-1618.
76. López-Farré A, Gómez-Garre D, Bernabeu F, López-Novoa JM: A role for endothelin in the maintenance of postischaemic renal failure in the rat. J Physiol 1991;444:513-522.
77. Gellai M, Jugus M, Fletcher T, Dewolf R, Nambi P: Reversal of postischemic acute renal failure with a selective endothelin-1 receptor antagonist in the rat. J Clin Invest 1994;93: 900-906.
78. Birck R, Knoll T, Braun C, Kirchengast M, Münter K, van der Woude FJ, Rohmeiss P: Improvement of postischemic acute renal failure with the novel orally active endothelin A receptor antagonist LU135252 in the rat. J Cardiovasc Pharmacol 1998;32:80-86.
79. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP: Nonpeptide endothelin receptor antagonists. V. Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995;275: 200-202.
80. Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, Ishikawa K, Watanabe K, Nishikibe M, Yano M, Ikemoto F: Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. EurJ Pharmacol 1992;221:77-83.
81. Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW: Effect of an endothelin-receptor antagonist on ischemic acute renal failure. Am J Physiol 1994;266:F135-F138.
82. Brooks DP, DePalma PD, Pullen M, Nambi P: Characterization of canine renal endothelin receptor subtypes and their function. J Pharmacol Exp Ther 1994;268:1091-1097.
83. Cristol JP, Warner TD, Thiemermann C, Vane JR: Mediation via different receptors of the vasoconstrictor effect of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol 1993;108:776-779.
84. Matsuura T, Miura K, Ebara T, Yukimura T, Yamanaka S, Kim S, Iwao H: Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br J Pharmacol 1997;122:81-86.
85. Kaasjager KA, Shaw S, Koomans HA, Rabelink TJ: Role of endothelin receptor subtypes in the systemic and renal response to endothelin-1 in humans. J Am Soc Nephrol 1997;8:32-39.
86. Ong AC, Jowett TP, Firth JD, Burton S, Karet FE, Fine LG: An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int 1995;48:390-401.
87. Perico N, Dadan J, Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990;1:76-83.
88. Langman LJ, Yatscoff RW: Comparison of the effects of cyclosporin G, cyclosporin A and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines. Ther Drug Monit 1994; 16:450-457.
89. Iwasaki S, Homma T, Kon V: Site-specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney Int 1994;45:592-597.
90. Lanese DM, Conger BD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993;91:2144-2149.
91. 2 receptor antagonists on cyclosporine A renal vasoconstriction. Am J Physiol 1994;267:F443-F449.
92. Brooks DP, Contino LC: Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB209670. Eur J Pharmacol 1995;294:571-576.
93. Kon V, Hunley TE, Fogo A: Combined antagonism of endothelin A/B receptors links endothdin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation 1995;60:89-95.
94. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, Epstein FH: Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992;3:58-65.
95. Heyman SN, Clark BA, Cantley L, Spokes K, Rosen S, Brezis M, Epstein FH: Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol 1993;28:313-318.
96. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH: Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993;44: 1217-1223.
97. Oldroyd S, Slee S, Haylor J, Morcos SK, Wilson C: Role for endothelin in the renal responses to radiocontrast media in the rat. Clin Sci 1994;87:427-434.
98. Pollock DM, Polakowski JS: Beneficial effect of ETA receptor blockade in radiocontrast-induced nephropathy in the rat (abstract). J Am Soc Nephrol 1995;6:667.
99. Bird JE, Giancarli MR, Megill JR, Durham SK: Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J Am Soc Nephrol 1996;7:1153-1157.
100. Simonson MS, Wann S, Meine P, Dubyak MM, Rester Y, Nakazato Y: Endothelin stimulates phospholipase C, Na/H exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708-712.
101. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S: Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 1990;258:C408-C415.
102. Macnulty EE, Plevin R, Wakelam MJ: Stimulation of the hydrolysis of phosphatidylinositol-4,5-biphosphate and phosphatidylcholine by endothelin, a complete mitogen for Rat-1 fibroblasts. Biochem J 1990;272:761-766.
103. Bard KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC: Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. J Clin Invest 1989;83: 708-712.
104. Bakris GL, Re RN: Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 1993;264: F937-F942.
105. Kohno M. Horio T, Yokokawa K, Yasunari K, Kurihara N, Takeda T: Endothelin modulates the mitogenic effect of PDGF on glomerular mesangial cells. Am J Physiol 1994;266: F894-F900.
106. Ruiz-Ortega M, Gomez-Garre D, Alcazar R, Palacios I, Bustos C, Gonzalez S, Plaza JJ, Gonzalez E, Egido J: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens 1994;12:551-558.
107. Hahn AWA, Regenass S, Kern F, Bühler FR, Resink TJ: Expression of soluble and insoluble fibronectin in rat aorta: Effects of angiotensin II and endothelin-1. Biochem Biophys Res Commun 1993;192:189-197.
108. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H: Effects of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic rat glomeruli. Diabetes 1995;44:895-899.
109. Benigni A, Perico N, Gaspari F, Zoja C, Bellizi L, Gabanelli M, Remuzzi G: Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991;260: F331-F339.
110. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L. Remuzzi G: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-358.
111. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440-444.
112. Benigni A, Zoja C, Corna D, Orisio S, Facchinetti D, Benatti L, Remuzzi G: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996;3:416-423.
113. Nabokov A, Ammann K, Wagner J, Gehlen F, Münter K, Ritz E: Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 1966;11:514-520.
114. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/WF1 mice. Renal Physiol Biochem 1993;16:233-243.
115. Nakamura T, Ebihara I, Tomoni Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-789.
116. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H: Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990;267:16-18.
117. Morabito E, Corsico N. Serafini S, Martelli EA: Elevated urinary excretion of endothelins in streptozotocin diabetic rats. Life Sci 1994; 54:197-200.
118. Fukui M, Nakamura T, Ebihara I, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 1993;122:149-156.
119. Nakamura T, Ebihara I, Shirato I, Fukui M, Tomino Y, Koide H: Endothelin-1 mRNA expression by peripheral blood monocytes in IgA nephropathy. Lancet 1993;342:1147-1148.
120. 2 in cold storage solution can reveal previous renal ischemic insults. Transplant Int 1994;7:11-16.
121. Büyükgebiz O, Aktan AÖ, Haklar G, Yalcin AS, Yegen C, Yalin R, Ercan ZS: BQ123, a specific endothelin receptor antagonist, prevents ischemia-reperfusion injury in kidney transplantation. Transplant Int 1996;9:201-207.
122. Braun C, Vetter S, Conzelmann T, Kirchengast M, van der Woude FJ, Rohmeiss P: Improvement of post-transplant acute renal failure in rats with the oral endothelin A-receptor antagonist LU 135252. 31th Annual meeting of the American Society of Nephrology (1998), Philadelphia, USA [abstract].
123. Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Ohlstein EH: A role for endogenous endothelin-1 in neointimal formation after rat carotid artery ballon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res 1994;1:190-197.
124. Watschinger B, Sayegh MH: Endothelin in organ transplantation. Am J Kidney Dis 1996;27:151-161.
125. Rohmeiss P, Braun C, Conzelmann T, Vetter S, Schaub M, Back WE, Kirchengast M, van der Woude FJ: Improvement of chronic renal allograft rejection in rats with the oral endothelin A-receptor antagonist LU 135252. 31th Annual meeting of the American Society of Nephrology (1998), Philadelphia, USA [abstract].
126. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim JH, Oechslin E, Schmitt R, Joncs R, Bertel O: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-736.
127. Sütsch G, Hunziker P, Kim JH, Bryzinski B, Bertel O, Kiowski W: The effect of prolonged endothelin-antagonist therapy with bosentan in severe chronic heart failure (abstract). Eur J Clin Invest 1996;26(suppl 1):293.
128. Schmitt R, Belz GG, Fell D, Lebmeier R, Prager G, Stahnke PL, Sittner WD, Karworth A, Jones CR: Effects of novel endothelin receptor antagonist bosentan in hypertensive patients. Abstracts of the European Society of Hypertension, 1995, p 170.
129. Krum H, Viskoper RJ, Lacouciere Y, Budde M, Charlton V: The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998;338:784-790.
130. Sütsch G, Fleisch M, Van XW, Wenzel R, Binggeli C, Bianchetti MC, Kiowski W, Luscher T: Acute hemodynamic and renal effects of the endothelin-1 receptor antagonist TAK-044 in patients without heart failure (abstract). J Am Coll Cardiol 1997;29(suppl A):444.